

532 Rec'd PCT/PTC 27 SEP 2000

FORM PTO-1390
(REV 11/99)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (if known, see 37 CFR 1.51)

09/647329

INTERNATIONAL APPLICATION NO.
PCT/GB99/00968INTERNATIONAL FILING DATE
March 26, 1999PRIORITY DATE CLAIMED
March 27, 1998

TITLE OF INVENTION

POLYMORPHISM: I: LINKAGE OF ASTHMA TO A LOCUS ON CHROMOSOME 2

APPLICANT(S) FOR DO/EO/US WILLIAM OSMOND CHARLES MICHAEL COOKSON; MIRIAM FLEUR MOFFATT;
SUMIT BHATTACHARYYA; NICHOLAS LEAVES

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:
Courtesy copy of published PCT application

430 Rec'd PCT/PTO 27 SEP 2000

U.S. APPLICATION NO. (If known, see 37 CFR 1.51)

INTERNATIONAL APPLICATION NO.

ATTORNEY'S DOCKET NUMBER

09/647329

PCT/GB99/00968

17. ☒ The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):

Neither international preliminary examination fee (37 CFR 1.482)
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO
and International Search Report not prepared by the EPO or JPO \$970.00

International preliminary examination fee (37 CFR 1.482) not paid to
USPTO but International Search Report prepared by the EPO or JPO \$840.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but
international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$760.00

International preliminary examination fee paid to USPTO (37 CFR 1.482)
but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00

International preliminary examination fee paid to USPTO (37 CFR 1.482)
and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

CALCULATIONS PTO USE ONLY

\$ 840

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30
months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	14 - 20 =		X \$18.00
Independent claims	2 - 3 =		X \$78.00

\$

\$

MULTIPLE DEPENDENT CLAIM(S) (if applicable)

+ \$260.00

\$

TOTAL OF ABOVE CALCULATIONS =

\$ 840

Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement
must also be filed (Note 37 CFR 1.9, 1.27, 1.28).

\$

SUBTOTAL =

\$

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30
months from the earliest claimed priority date (37 CFR 1.492(f)).

\$

TOTAL NATIONAL FEE =

\$ 840

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property

\$

TOTAL FEES ENCLOSED =

\$ 840

Amount to be:
refunded

\$

charged

\$

a. ☐ A check in the amount of \$_____ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 20-1430 in the amount of \$ 840 to cover the above fees.
A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
overpayment to Deposit Account No. 20-1430. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR
1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Joe Liebeschuetz
Townsend and Townsend and Crew LLP
Two Embarcadero Center, 8th fl.
San Francisco, CA 94111

SIGNATURE:

Joe Liebeschuetz

NAME

37,505

REGISTRATION NUMBER

430 Rec'd PCT/PTO 27 SEP 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. National Phase of

PCT/GB99/00968 of:

William Osmond Charles Michael
Cookson et al.

Application No.: Unassigned

Filed: Herewith

For: POLYMORPHISM I: LINKAGE
OF ASTHMA TO A LOCUS ON
CHROMOSOME 2PRELIMINARY AMENDMENTBox PCT
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination of the above-referenced application, please enter the following amendments and remarks.

IN THE CLAIMS:

Please amend claims 7, 8, 12 and 14 as follows. All pending unamended claims have been reproduced in small type for ease of reference.

- 1 1. (Amended under Article 34) A method for diagnosing an individual as being
2 asthmatic, or as having a predisposition to asthma, which method comprises demonstrating in a nucleic acid
3 sample taken from an individual the presence or absence of an allele which is associated with asthma, wherein the
4 allele is situated at a locus in a region of chromosome 2 of up to 1 megabase in length, which region contains the
5 locus D2S308.
- 1 2. (As filed) The method according to claim 1, wherein the method comprises the steps
2 of:
 - 3 (i) Providing a suitable tissue sample from the individual;
 - 4 (ii) Preparing from the tissue sample a nucleic acid sample
 - 5 (iii) Analyzing the nucleic acid sample for the presence or absence of the allele.

1 3. (As filed) The method according to claim 2, wherein prior to analysis, the locus at
2 which the allele is situated is amplified.

1 4. (As filed) The method according to claim 3, wherein the amplification is by the PCR.

1 5. (As filed) The method according to any one of claims 1 to 4, wherein the locus at
2 which the allele is situated comprises microsatellite repeats of variable lengths.

1 6. (As filed) The method according to claim 5, wherein amplification is performed using
2 a pair of primers each of which hybridizes under suitably stringent conditions to a region either side of the
3 microsatellite repeats.

1 7. (Amended) The method according to [any one of] claim[s] 1 [to 6],
2 wherein the allele for identification is D2S308*3.

1 8. (Amended) The method according to [any one of] claim[s] 3 [to 7],
2 wherein the analysis is carried out by size separation of amplification products.

1 9. (As filed) The method according to claim 6, wherein the primers in the pair of primers
2 comprise the oligonucleotide sequences identified by SEQ ID NO: 1 and SEQ ID NO: 2 or substantially similar
3 sequences.

1 10. (As filed) A pair of oligonucleotide primers for amplification of an allele which is
2 associated with asthma, which allele is situated at a locus in a region of chromosome 2 of up to 1 megabase in
3 length, which region contains the locus D2S308.

1 11. (As filed) The pair of oligonucleotide primers according to claim 10, one of which is
2 labeled with a detectable marker.

1 12. (Amended) The pair of oligonucleotides according to claim 10 [or claim
2 11], capable of hybridizing under suitably stringent conditions to a region either side of a
3 region of microsatellite repeats at D2S308.

1 13. (As filed) The pair of oligonucleotide primers according to claim 12, comprising the
2 oligonucleotide sequences identified by SEQ ID NO: 1 and SEQ ID NO: 2 or substantially similar sequences.

- 1 14. (Amended) An assay kit which comprises the pair of oligonucleotide
2 primers according to [any one of] claim[s] 10 [to 13]..

REMARKS

Amendments to claims 7, 8, 12 and 14 have been made to remove multiple claim dependency.

CONCLUSION

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,



Joe Liebeschuetz
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Telephone: (650) 326-2400
Facsimile: (650) 326-2422
JOL:dms
PA 3099597 v1

09/647329

430 Rec'd PCT/PTO 27 SEP 2000

POLYMORPHISM I : LINKAGE OF ASTHMA TO A LOCUS ON CHROMOSOME 2

This invention is concerned with methods for the diagnosis of
5 asthma and with materials and methods relating thereto.

Asthma is a disease which is becoming more prevalent and is
the most common disease of childhood (1). Most asthma in children and
young adults is initiated by IgE mediated allergy (atopy) to inhaled allergens
such as house dust mite and cat dander. However, not all asthmatics are
10 atopic, and most atopic individuals do not have asthma, so that factors in
addition to atopy are necessary to induce the disease (2,3). Asthma is
strongly familial, and is due to the interaction between genetic and
environmental factors. The genetic factors are thought to be variants of
normal genes ("polymorphisms") which alter their function to predispose to
15 asthma.

Asthma may be identified by recurrent wheeze and intermittent
air flow limitation. An asthmatic tendency may be quantified by the
measurement of bronchial hyper-responsiveness in which an individual's
dose-response curve to a broncho-constrictor such as histamine or
20 methacholine is constructed. The curve is commonly summarised by the dose
which results in a 20% fall in air flow (PD20) or the slope of the curve between
the initial air flow measurement and the last dose given (slope).

In the atopic response, IgE is produced by B-cells in response to
allergen stimulation. These antibodies coat mast cells by binding to the high
25 affinity receptor for IgE (FcεRI). When a multivalent allergen binds to an IgE-
coated mast cell, the cross-linking of adjacent IgEs by allergen initiates a
series of cellular events leading to the destabilisation of the cell membrane

and release of inflammatory mediators. This results in mucosal inflammation, wheezing, coughing, sneezing and nasal blockage.

Atopy can be diagnosed by (i) a positive skin prick test in response to a common allergen; (ii) detecting the presence of specific serum IgE for allergen; or (iii) by detecting elevation of total serum IgE.

Genetic factors underlying a disease may be identified through localisation to particular chromosomal regions by genetic linkage. Genetic linkage is established by the study of families. It relies on matching the inheritance of disease with genetic polymorphisms of known localisation (known as "genetic markers"). In a complex disease such as asthma, genetic linkage will typically localise genes to within 10 - 20 Megabases (Mb) of DNA. A region of this size may contain 350 - 700 genes, and will be too large to permit immediate identification of the disease-causing gene.

Closer localisation of disease-causing genes may be accomplished by the detection of associations between particular alleles and the disease phenotype. Over short segments of DNA, distinctive alleles of the individual polymorphisms will show non-random association with alleles of neighbouring polymorphisms. This phenomenon, known as "linkage disequilibrium" occurs over 50-500 Kilobases (Kb) of DNA. Linkage disequilibrium may be detected by the study of individuals as well as by the study of families.

Disease-causing alleles will be in linkage disequilibrium with non-functional polymorphisms from the same chromosomal segment. It is therefore possible to detect allelic association with disease from particular chromosomal segments, without identifying the exact polymorphism and gene underlying the disease state.

The detection of allelic association may therefore give information as to disease susceptibility in a particular individual. Furthermore,

allelic association is indicative of a disease-causing gene being present within 500 Kb of DNA in either direction from the allele (i.e. 1 Mb in total). Such a region may contain only 30 genes, within which the identification of the disease-causing gene is possible.

5 The presence of linkage disequilibrium also means that other polymorphisms may be anticipated to associate with disease, and that these additional polymorphisms will also be diagnostic of disease susceptibility in particular individuals.

Genetic associations with atopy have been demonstrated.

10 WO 95/05481 discloses that variants of the gene encoding the β -subunit of the high-affinity receptor for IgE ($\text{Fc}\epsilon\text{RI}\beta$) are associated with atopy. It teaches a method for diagnosing atopy which is based upon the demonstration of the presence or absence of one of two variants in a specific portion of the DNA sequence of the gene encoding $\text{Fc}\epsilon\text{RI}\beta$, located near the
15 commencement of exon 6 of the $\text{Fc}\epsilon\text{RI}\beta$ gene on chromosome 11. A further variant has also been found in which the unusual variant sequence is in the coding sequence for the C-terminal cytoplasmic tail of $\text{Fc}\epsilon\text{RI}\beta$ (4).

 Tumour Necrosis Factor (TNF) is a pro-inflammatory cytokine that is found in increased concentration in asthmatic airways (5). We have
20 previously shown that polymorphisms within the TNF gene are associated with an increased risk of asthma (6).

 The known polymorphisms do not account for all of the genetic factors which predispose to asthma. In particular, asthma is not necessarily an atopic disease. Identification of further genetic polymorphisms linked to
25 asthma will allow the identification of children at risk of asthma before the disease has developed (for example immediately after birth), with the potential for prevention of disease. The presence of particular polymorphisms may predict the clinical course of disease (e.g. severe as opposed to mild) or the

response to particular treatments. This diagnostic information will be of use to the health care, pharmaceutical and insurance industries.

It has now been discovered that a genetic polymorphism known as D2S308*3 near the IL1 gene cluster on chromosome 2 is associated with asthma and can be used as a diagnostic tool.

Interleukin 1 (IL1) is another pro-inflammatory cytokine which is increased in asthmatic airways (5). IL1 is part of a gene family, localised on the long arm of chromosome 2 (7). Not all members of the gene family have been identified. The members of the family may share similar functions.

The invention therefore provides a method for diagnosing an individual as being asthmatic, or as having a predisposition to asthma, which method comprises demonstrating in the individual the presence or absence of an allele which is associated with asthma, wherein the allele is situated at a locus in a region of chromosome 2 of up to 1 megabase in length, which region contains the locus D2S308.

The 1 Mb region of chromosome 2 in which the D2S308 locus is situated flanks the D2S308 locus. Thus, the specific allele D2S308*3, or other unusual polymorphisms in the region which are associated with asthma, may be the subject of identification in the method according to the invention.

Equally, two or more such alleles may be the subject of identification.

Current diagnostic methods involving detection at the nucleic acid level normally comprise the steps of:

- (i) obtaining a suitable tissue sample from the individual;
- (ii) preparing from the tissue sample a nucleic acid sample;
- (iii) analysing the nucleic acid sample for the presence or absence of the relevant nucleic acid sequence, such as a specific allele.

Preferably, an amplification step is performed prior to the analysis, such that the locus at which the allele is situated is amplified. A preferred amplification technique is the PCR, although any suitable method of nucleic acid amplification may be employed.

5 In further aspects, the invention provides a pair of oligonucleotide primers for amplification of an allele which is associated with asthma, which allele is situated at a locus in a region of chromosome 2 of up to 1 megabase in length, which region contains the locus D2S308; and an assay kit comprising the pair of oligonucleotide primers.

10 The specific allele for identification may take the form of microsatellite repeats, which are nucleotide sequences containing short, repeated nucleotide motifs, usually a dinucleotide or a trinucleotide motif. A pair of primers which hybridize under suitably stringent conditions, to sequences at a position on either side of the microsatellite repeats, may be
15 used to amplify the microsatellite repeats by PCR. Differences in the number of repeats are recognised by size differences in the PCR products. An allele which has a specified number of repeats and therefore a known size can thus be identified. D2S308*3 is one such allele.

The primers employed in the method comprise nucleic acid
20 sequences which are complementary to, or substantially complementary to unique sequences either side of the microsatellite repeats, such that only the relevant polymorphic region of the genome is amplified. The conditions under which the amplification is performed are gauged such that specific hybridization of the primers to the flanking sequences occurs and non-specific
25 hybridization is avoided. The hybridization conditions are suitably stringent for that purpose. Standard techniques can be used to identify an appropriate set of reaction conditions.

Typically, the PCR products are detected by means of a detectable label attached to one of the PCR primers. Alternatively another form of labeling may be used such as a labeled sequence specific probe which hybridizes to the amplified sequences. The label may be a fluorescent or other label. The PCR products are subjected to size determination, typically involving size-separation for example by gel electrophoresis, and the presence or absence of the allele of interest is determined.

It will be evident that the invention is not limited with regard to the manner in which the presence or absence of the allele of interest is determined. The labeling, detection, separation or any other aspect of the method as described here may be replaced by other suitable known techniques and reagents.

The allele for identification may be an allele other than D2S308*3 which is in linkage disequilibrium with D2S308*3 and is associated with asthma. This includes alleles of both functional and non-functional polymorphisms. Functional polymorphisms include polymorphisms within genes, usually within coding sequences of genes. Non-functional polymorphisms are polymorphisms which do not themselves cause the disease.

This invention will now be further described in the Examples section which follows. The Examples are intended to be illustrative and do not limit the scope of the invention in any way.

EXAMPLES

25 Description of Laboratory Testing

Subjects

Three panels of subjects have been studied.

Panel A consisted of 80 nuclear families sub-selected from an

Australian population sample of 230 families (8). The panel contained a total of 203 offspring forming 172 sib-pairs. 12% of the children were asthmatic.

Panel B consisted of 77 nuclear and extended families recruited from asthma and allergy clinics in the United Kingdom (9). These families
5 contained 215 offspring (268 sib-pairs) of which 56% were asthmatic.

Panel C consisted of 87 nuclear families recruited through a child attending an asthma clinic in the Oxford region. The families contained 216 offspring (148 sibling pairs), of whom 44% were asthmatic.

10 Phenotyping

The subjects were administered a modified British MRC respiratory questionnaire. "Asthma" was defined as a positive answer to the questions "Have you ever had an attack of asthma?" and "If yes, has this happened on more than one occasion?". "Wheeze" was defined as a positive
15 answer to the question "Has your chest ever sounded wheezing or whistling?" and "If yes, has this happened on more than one occasion?". The total serum IgE was measured in all children. Skin tests to house dust mite and grass pollen were carried out.

20 Genotyping

The microsatellite markers D2S340, D2S160, IL1A, D2S308 and D2S121 were typed by semi-automated fluorescent methods, as described previously (8). These markers cover a distance of 12 centiMorgans (approximately 12 million base pairs of DNA), containing the IL1 cluster of
25 genes.

The polymerase chain reaction (PCR) primer sequences for the markers were as follows:

D2S308 5' GCC AGG TGG GTC TGG A (SEQ ID NO: 1)

UD2S308 5' TGG TTT TTT CAA GGG ATT TTC T (SEQ ID NO: 2)

D2S340 5' CTG GAA CCC CAG TAG C (SEQ ID NO: 3)

UD2S340 5' CTT TGC CCA GTT TTG C (SEQ ID NO: 4)

D2S160 5' TGT ACC TAA GCC CAC CCT TTA GAG C (SEQ ID NO: 5)

5 UD2S160 5' TGG CCT CCA GAA ACC TCC AA (SEQ ID NO: 6)

IL1A 5' GCC TAG TGA GTG TGG AAG ACA TTG (SEQ ID NO: 7)

UIL1A 5' CAG CAC TGG TTG GTC TTC ATC TTG (SEQ ID NO: 8)

D2S121 5' GCT GAT ATT CTG GTG GGA AA (SEQ ID NO: 9)

UD2S121 5' GGC AAG AGC AAA ACT CTGTC (SEQ ID NO: 10)

10 The polymerase chain reaction conditions were as follows:

The reaction volumes were 10 μ l, containing 50ng of genomic DNA, 200mM dNTPs, 1 x NH₄⁺ buffer, 50ng oligonucleotide primers (forward labelled fluorescently), 0.5 to 3.0mM MgCl₂ and 0.2U Taq polymerase. Cycling conditions were 1 min at 95°C, 1min at 55°C and 45s at 72°C; 28 cycles were

15 used. PCRs were performed on an Hybaid Omnigene thermal cycler.

Electrophoresis and allele scoring were as follows:

PCR products were mixed with a size standard (GS350 TAM) in loading buffer (80% (v/v) formamide, 20% (v/v) 50mM EDTA. 0.1% (w/v) blue dextran).

Samples were denatured at 95°C for 4min immediately prior to loading onto a

20 6% polyacrylamide gel and were electrophoresed at 800v for 6h on an Applied Biosystems (ABI) 373 DNA sequencer. Allele sizes were assigned using the ABI GENESCAN and ABI GENOTYPER software.

Linkage and Association Analysis

25 Linkage was tested against asthma and the associated

phenotypes of wheeze, the skin test index, the total serum IgE and the residual IgE (the proportion of the total IgE not attributable to specific allergy)(8,10). Linkage was assessed by standard sib-pair methods as described (8).

- 5 Association was tested against the phenotype of asthma by the Transmission Disequilibrium Test.

Results

- Genetic linkage to asthma-associated phenotypes was detected in Panel A
10 and Panel B subjects as follows (genetic linkage to these phenotypes was not detected in Panel C subjects):

	θ	Skin Test Index		Residual IgE		Wheeze	
		Panel A	Panel B	Panel A	Panel B	Panel A	Panel B
D2S340	0.04	-	-	-	-	$p < 0.01$	-
D2S160	0.02	-	$p < 0.005$	$p < 0.01^{**}$	-	$p < 0.01$	$p < 0.05$
IL1A	0.05	-	-	-	-	$p < 0.0005$	-
D2S308	0.01	-	-	-	-	$p < 0.005$	-
D2S121		-	-	-	-	$p < 0.01$	-

*recombination fraction: 0.01 approximates 1 million base pairs

- 15 ** $p < 0.00001$ in maternal meioses

Genetic linkage between the marker D2S160 and asthma was detected at $p = 0.09$ in Panel A, $p = 0.01$ in Panel B, and $p = 0.12$ in Panel C. The combined significance of linkage was $p = 0.008$.

- 20 These results indicate that a gene influencing asthma lies within the D2S340 - D2S121 interval. Based on the current linkage information, the precise localisation of the putative asthma gene within the interval is uncertain.

Association with D2S308 allele 3

Each of the markers was then tested for association with asthma phenotype. Association was seen in each panel for allele 3 of D2S308 (D2S308*3). This allele is 228 base pairs in size, using the primers described above. (Other primers can be designed and their amplification product size determined for D2S308*3, using known sequence information (11).) The results of TDT testing were as follows:

	Transmitted	<u>Not Transmitted</u>	p
Panel A	14	4	p=0.015
Panel B	55	29	p=0.003
Panel C	49	32	p=0.037
Combined	118	65	p=0.00009

The results indicate that D2S308*3, near the Interleukin 1 gene cluster on chromosome 2, shows a strong reproducible association with asthma in three diverse panels of subjects. It may therefore be inferred that a gene influencing asthma is present within 500 kilobases in either direction of D2S308.

REFERENCES

1. Strachan, D.P., Anderson, H.R., Limb, E.S., O'Neill, A. and Wells, N. (1994). A national survey of asthma prevalence, severity, and treatment in Great Britain. *Arch. Dis. Child.*, 70, 174-178.

2. Fraser, R.S., Paré, J.A.P., Fraser, R.G. and Paré, P.D., eds. (1994) Synopsis of Diseases of the Chest. WB Saunders Company, Philadelphia: 635-53.
3. Djukanovic, R., Roche, W.R., Wilson, J.W., Beasley, C.R., Twentyman, O.P., Howarth, R.H. and Holgate S.T. (1990) Mucosal inflammation in asthma. *Am. Rev. Respir. Dis.*, **142**, 434-457.
4. Hill, M.R. and Cookson, W.O.C.M. (1996). A new variant of the β subunit of the high-affinity receptor for Immunoglobulin E (Fc ϵ RI- β E237G): Associations of measures of atopy and bronchial hyper-responsiveness. *Hu. Mol. Gen.* **5**, 959-962.
5. Broide, D.H., Lotz, M., Cuomo, A.J., Coburn, D.A., Federman, E.C. and Wasserman, S.I. (1992) Cytokines in symptomatic asthma airways. *J. Allergy Clin. Immunol.* **89**, 958-967.
6. Moffatt M.P, Cookson WOCM. Tumour Necrosis Factor Haplotypes. and Asthma. *Hum Molec Genet* 1997; **6**: 551-554.
7. Bailly S, di Giovine FS, Blakemore A.I.F, Duff G.W. Genetic polymorphism of human interleukin-1 α . *Eur J Immunol* 1993; **23**: 1240-1245.
8. Daniels S.E, Bhattacharyya S, James A, Leaves N.I, Young A, Hill M.R, Faux J.A, Ryan G.F, le Söuef P.N, Lathrop G.M, Musk A.W, Cookson W.O.C.M. A genome-wide search for quantitative trait loci underlying asthma. *Nature* 1996; **383**: 247-250.
9. Sandford A.J, Shirakawa T, Moffatt M.F, Daniels S.E, Ra C, Faux J.A, Young R.P, Nakamura Y, Lathrop G.M, Cookson W.O.C.M Cookson, Hopkin J.M, Localisation of atopy and the β subunit of Fc ϵ RI receptor for IgE on chromosome 11q. *Lancet* 1993; **341**: 332-334.
10. Dizier M.H, Hill M, James A, Faux J, Ryan G, le Söuef P, Lathrop M, Musk A.W, Demenais F, Cookson W. Detection of a recessive major gene for

11. Dib S. et al. A comprehensive map of the human genome based on 5264 microsatellites. *Nature* 1996; **380**: 152-154.

CLAIMS

1. A method for diagnosing an individual as being asthmatic, or as having a predisposition to asthma, which method comprises demonstrating in a nucleic acid sample taken from an individual the presence or absence of an allele which is associated with asthma, wherein the allele is situated at a locus in a region of chromosome 2 of up to 1 megabase in length, which region contains the locus D2S308.
2. The method according to claim 1, wherein the method comprises the steps of:
 - (i) providing a suitable tissue sample from the individual;
 - (ii) preparing from the tissue sample a nucleic acid sample;
 - (iii) analysing the nucleic acid sample for the presence or absence of the allele.
3. The method according to claim 2, wherein prior to analysis, the locus at which the allele is situated is amplified.
4. The method according to claim 3, wherein the amplification is by the PCR.
5. The method according to any one of claims 1 to 4, wherein the locus at which the allele is situated comprises microsatellite repeats of variable lengths.
6. The method according to claim 5, wherein amplification is performed using a pair of primers each of which hybridizes under suitably stringent conditions to a region either side of the microsatellite repeats.
7. The method according to any one of claims 1 to 6, wherein the allele for identification is D2S308*3.

8. The method according to any one of claims 3 to 7, wherein the analysis is carried out by size separation of amplification products.
9. The method according to claim 6, wherein the primers in the pair of primers comprise the oligonucleotide sequences identified by SEQ ID NO: 1 and SEQ ID NO: 2 or substantially similar sequences.
10. A pair of oligonucleotide primers for amplification of an allele which is associated with asthma, which allele is situated at a locus in a region of chromosome 2 of up to 1 megabase in length, which region contains the locus D2S308.
11. The pair of oligonucleotide primers according to claim 10, one of which is labelled with a detectable marker.
12. The pair of oligonucleotides according to claim 10 or claim 11, capable of hybridising under suitably stringent conditions to a region either side of a region of microsatellite repeats at D2S308.
13. The pair of oligonucleotide primers according to claim 12, comprising the oligonucleotide sequences identified by SEQ ID NO: 1 and SEQ ID NO: 2 or substantially similar sequences.
14. An assay kit which comprises the pair of oligonucleotide primers according to any one of claims 10 to 13.

276

Rev. 11-3/98

Effective March 1998

DECLARATION AND POWER OF ATTORNEY FOR U.S. PATENT APPLICATION

(X) Original () Supplemental () Substitute () PCT () DESIGN

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I verily believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Title: POLYMORPHISM I: LINKAGE OF ASTHMA TO A LOCUS ON CHROMOSOME 2

of which is described and claimed in:

() the attached specification, or

(X) the specification in application Serial No. 09/647,329, filed September 27, 2000, and with amendments through (if applicable), or

() the specification in International Application No. , filed , and as amended on (if applicable).

I hereby state that I have reviewed and understand the content of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge my duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim priority benefits under Title 35, United States Code, §119 (and §172 if this application is for a Design) of any application(s) for patent or inventor's certificate listed below and have also identified below any application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

COUNTRY	APPLICATION NO.	DATE OF FILING	PRIORITY CLAIMED
Great Britain	9806652.5	March 27, 1998	Yes

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	U.S. FILING DATE	STATUS: PATENTED, PENDING, ABANDONED

And I hereby appoint Michael R. Davis, Reg. No. 25,134; Matthew M. Jacob, Reg. No. 25,154; Jeffrey Nohon, Reg. No. 25,408; Warren M. Check, Jr., Reg. No. 33,367; Nils Pedersen, Reg. No. 33,145; and Charles R. Watts, Reg. No. 33,142, who together constitute the firm of WENDEROTH, LIND & PONACK, L.L.P., jointly and severally, attorneys to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected therewith.

I hereby authorize the U.S. attorneys named herein to accept and follow instructions from Kilburn and Strode as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and myself. In the event of a change in the persons from whom instructions may be taken, the U.S. attorneys named herein will be so notified by me.

Send Correspondence to

Direct Telephone Calls to:

WENDEROTH, LIND & PONACK, L.L.P.
 2033 K Street, N.W., Suite 800
 Washington, D.C. 20006

WENDEROTH, LIND & PONACK, L.L.P.
 Area Code (202) 721-8200

Direct Facsimile Messages to:
 Area Code (202) 721-8250

Full Name of First Inventor	FAMILY NAME <u>COOKSON</u>	FIRST GIVEN NAME <u>William</u>	SECOND GIVEN NAME <u>Osmond Charles Michael</u>
Residence & Citizenship	CITY <u>Oxford</u>	STATE OR COUNTRY <u>Great Britain</u>	COUNTRY OF CITIZENSHIP <u>Great Britain</u>
Post Office Address	ADDRESS <u>67 Hilltop Road</u>	CITY <u>Oxford</u>	STATE OR COUNTRY <u>Great Britain</u> ZIP CODE <u>OX4 1PD</u>
Full Name of Second Inventor	FAMILY NAME <u>MOFFATT</u>	FIRST GIVEN NAME <u>Miriam</u>	SECOND GIVEN NAME <u>Fleur</u>
Residence & Citizenship	CITY <u>Langford Village, Bicester</u>	STATE OR COUNTRY <u>Great Britain</u>	COUNTRY OF CITIZENSHIP <u>Great Britain</u>
Post Office Address	ADDRESS <u>30 Lapwing Close</u>	CITY <u>Langford Village, Bicester</u>	STATE OR COUNTRY <u>Great Britain</u> ZIP CODE <u>OX6 0XR</u>
Full Name of Third Inventor	FAMILY NAME <u>BHATTACHARYYA</u>	FIRST GIVEN NAME <u>Sumit</u>	SECOND GIVEN NAME
Residence & Citizenship	CITY <u>Stapleford, Cambridgeshire</u>	STATE OR COUNTRY <u>Great Britain</u>	COUNTRY OF CITIZENSHIP <u>Great Britain</u>
Post Office Address	ADDRESS <u>20 Bury Road</u>	CITY <u>Stapleford, Cambridgeshire</u>	STATE OR COUNTRY <u>Great Britain</u> ZIP CODE <u>CB2 5BP</u>
Full Name of Fourth Inventor	FAMILY NAME <u>LEAVES</u>	FIRST GIVEN NAME <u>Nicholas</u>	SECOND GIVEN NAME
Residence & Citizenship	CITY <u>Sandhills, Oxford</u>	STATE OR COUNTRY <u>Great Britain</u>	COUNTRY OF CITIZENSHIP <u>Great Britain</u>
Post Office Address	ADDRESS <u>47 Burdell Avenue</u>	CITY <u>Sandhills, Oxford</u>	STATE OR COUNTRY <u>Great Britain</u> ZIP CODE <u>OX3 8EE</u>
Full Name of Fifth Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE
Full Name of Sixth Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE

I further declare that all statements made herein of my own knowledge are true, and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1st Inventor	<u>William Cookson</u>	X	Date	<u>23.1.01</u>	X
	William Osmond Charles Michael COOKSON				
2nd Inventor	<u>Miriam Fleur MOFFATT</u>	X	Date	<u>23.1.01</u>	X
	Miriam Fleur MOFFATT				
3rd Inventor	<u>Sunita BHATTACHARYA</u>	X	Date	<u>14/2/01</u>	X
	Sunita BHATTACHARYA				
4th Inventor	<u>Nicholas LEAVES</u>	X	Date	<u>31.1.01</u>	X
	Nicholas LEAVES				
5th Inventor			Date		
6th Inventor			Date		

The above application may be more particularly identified as follows:

U.S. Application Serial No. 09/647,329 Filing Date September 27, 2000

Applicant Reference Number P30627US/KVC/PS/CF Atty Docket No. 2000-1718

Title of Invention POLYMORPHISM I: LINKAGE OF ASTHMA TO A LOCUS ON CHROMOSOME 2